An Overview of Phase II Trial Results: Irinotecan Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer

ONCOLOGY

Volumn 12, Issue 8 SUPPL., 1998, Pages 79-83

  Devore III, Russell ^a   Johnson, David ^a   Crawford, Jeffrey ^b   Dimery, Isaiah ^c   Eckardt, John ^d   Gail Eckhardt, S ^e  

^a VANDERBILT UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d ST JOHN S MERCY MEDICAL CENTER   (United States)

^e University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE II; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS;

EID: 0031795670     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kudoh S, Takada M, Masuda N, et al: Enhanced antitumor efficacy of the combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993.
2. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly IV infusions of CPT-11, a new derivative of camptothecin in treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991.
3. Shinkai T, Arioka H, Kunikane H, et al: Phase I clinical trial of irinotecan and cisplatin in combination with a fixed dose of vindesine in advanced non-small-cell lung cancer. Cancer Res 54:2636-2642, 1994.
4. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony stimulating factor support for advanced lung cancer. J Clin Oncol 12:1833-1841, 1994.
5. Nakai H, Fukuoka M, Furuse K, et al: An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 18:607-612, 1991.
6. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993.
7. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small- cell lung cancer. J Clin Oncol 10:16-20, 1992.
8. Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992.
9. Baker L, Khan R, Lynch N, et al: Phase II study of irinotecan in advanced non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 16:461a, 1997.
10. Ueng L-M, Kohlhagen G, Gupta M, et al: Trapping of DNA topoisomerase I in damaged DNA: Effects of base mismatches, abasic sites, and nicks in the absence and presence of camptothecin. Proc Am Assoc Clin Res 37:435, 1996.
11. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cis-diaminedichloroplatinum (II- induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous carcinoma cells. Int J Cancer 62:70-75, 1995.
12. Fukuda M, Nishiio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small- cell lung cancer cells. Cancer Res 56: 789-793, 1996.
13. Cella D, Tulsky D, Gray G: The Functional Assessment of Cancer Therapy scale. Development and validation of the general measure. J Clin Oncol 11:570-579, 1993.
14. Bonomi P: Non-small-cell lung cancer chemotherapy, in Pass HI, Mitchell JB, Johnson DH, et al (eds): Lung Cancer, pp 811-823. Philadelphia, Lippincott-Raven, 1995.
15. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11:1391-1402, 1993.
16. Rowinsky EK, Ettinger DS: Drug development and new drugs for lung cancer, in Pass HI, Mitchell JB, Johnson DH, et al (eds): Lung Cancer, pp 793-810. Philadelphia, Lippincott-Raven, 1995.
17. Haddock MG, Ames MM, Bonner JA: Assessing the interaction of irradiation with etoposide or idarubicin Mayo Clin Proc 70: 1053- 1054, 1995.
18. Minehan K, Bonner JA: The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatment. Life Sci 53:PL237-242, 1993.
19. Kingma PS, Corbett AH, Burcham PC, et al: Abasic sites stimulate double stranded DNA cleavage mediated by topoisomerase II. J Biol Chem 270:21441-21444, 1995.
20. Saltz L, Kanowitz J, Kelsen D, et al: Phase I study of weekly cisplatin plus irinotecan in patients with advanced solid tumors (abstract). Proc Am Soc Clin One 15:484, 1996.